MetaCap

BrainsWay (BWAY) vs Neuropace (NPCE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BrainsWay (BWAY) has outperformed Neuropace (NPCE) over the past year, gaining 13.9% versus a loss of 44.6%. Over five years, BWAY leads with a +130.7% price change compared with -32.8% for NPCE. BrainsWay is the larger company by market cap ($341.3 million vs $273.9 million), about 1.2 times the size.

BrainsWay converts more of its revenue into profit, with a net margin of 7.1% versus -21.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BWAY+13.90%NPCE-44.60%
+140%+42%-56%
Nov 21, 20251 yearNov 20, 2026
BWAY+113.60%NPCE-32.91%
+354%+122%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BWAY versus NPCE key metrics
MetricBWAYNPCE
Share price$8.48$7.95
Market cap$341.35M$273.89M
1-day change-2.86%-2.33%
YTD return-10.83%-48.51%
1-year return+13.90%-44.60%
5-year return+130.75%-32.80%
P/E ratio (TTM)35.33—
Forward P/E16.96—
EPS (TTM)$0.24$-0.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.02M$99.99M
Revenue growth (YoY)+29.04%+25.13%
Net income (latest FY)$2.92M$-21.46M
Gross margin74.56%77.23%
Operating margin3.39%-16.34%
Net margin7.12%-21.47%
52-week high$17.40$19.60
52-week low$7.30$5.46
Distance from 52-week high-51.26%-59.44%
Analyst consensusstrong_buybuy
Avg. price target upside+127.24%+53.71%
Average volume110.35K270.76K
Shares outstanding40.25M34.45M
Employees129216
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BWAY has outperformed NPCE by 58.5 percentage points over the past year.
  • BrainsWay is more profitable, keeping 7.1 cents of every revenue dollar as net income versus -21.5 cents for Neuropace.

About BrainsWay

BWAY stock →

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.

Health Care · Medical/Dental Instruments · 129 employees

About Neuropace

NPCE stock →

NeuroPace, Inc. operates as a medical device company in the United States.

Health Care · Medical/Dental Instruments · 216 employees

BWAY vs NPCE FAQ

Which is bigger, BrainsWay or Neuropace?

BrainsWay (BWAY) is larger, with a market capitalization of $341.35M compared with $273.89M for Neuropace (NPCE).

Which stock has performed better over the past year, BWAY or NPCE?

BWAY returned +13.90% over the past 12 months, compared with -44.60% for NPCE (price return, excluding dividends). Past performance does not predict future results.

Are BrainsWay and Neuropace in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons